Publications by authors named "F Vergez"
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini-consolidations (idarubicin 8 mg/m day 1, cytarabine 50 mg/m/12 h, day 1-5) and IDAC.
View Article and Find Full Text PDFArticle Synopsis
- Adult T-cell acute lymphoblastic leukemia (T-ALL) has a low survival rate after it relapses, particularly the early T-cell precursor subtype, which shares similarities with acute myeloid leukemia.
- A case study is presented where a patient relapsed just 3 months post allogeneic stem cell transplantation but achieved complete remission through treatment with azacitidine and has remained on therapy for 9 years.
- The discussion highlights the biological factors contributing to this long-term response and explores the potential benefits of combining hypomethylating agents like azacitidine with other drugs, such as venetoclax, for improved outcomes.
Article Synopsis
- Acute myeloid leukemia (AML) is a difficult-to-treat blood cancer, mainly due to the presence of leukemic stem cells (LSCs) that lead to treatment resistance and relapse.
- This research focuses on how the quiescence (dormancy) of LSCs and related molecular mechanisms impact AML development, revealing that quiescent LSCs have a distinct gene signature and increased autophagic activity that helps them survive.
- The study identifies nuclear receptor coactivator 4 (NCOA4) as a key player in iron metabolism for quiescent LSCs, showing that inhibiting NCOA4 can effectively target these cells without harming normal blood progenitors, highlighting its potential as
Article Synopsis
- Venetoclax-azacitidine is the standard treatment for unfit acute myeloid leukemia patients, but there is limited data on how long patients should continue therapy if they cannot tolerate it.
- In a study analyzing patients who stopped treatment due to poor tolerance, those who discontinued showed comparable outcomes to those who continued with azacitidine alone, with median overall survival of 44 months for newly diagnosed patients.
- The findings suggest that patients who stop treatment while in remission can have favorable outcomes, indicating a need for further controlled trials to explore optimal treatment durations.
Article Synopsis
- CD38-targeting immunotherapy combined with lenalidomide and dexamethasone is the current best standard of care for newly diagnosed multiple myeloma patients who can't undergo transplants.
- A phase 3 study involving 270 patients tested the effectiveness of adding weekly bortezomib to this regimen, comparing the outcomes of the combination (Isa-VRd) against the standard (IsaRd).
- Results showed a significantly higher rate of minimal residual disease negativity at 18 months and better response rates in the Isa-VRd group, suggesting it could become the new standard of care for these patients.